Related Experiment Video

Updated: May 18, 2026

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
08:57

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Published on: May 17, 2024

Role of germline genetic factors in MPN pathogenesis

Ashot S Harutyunyan1, Robert Kralovics

  • 1CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 14, BT25.3, Vienna 1090, Austria.

Hematology/Oncology Clinics of North America
|September 27, 2012
PubMed

Insights

Hereditary factors significantly contribute to myeloproliferative neoplasms (MPNs) pathogenesis. Germline variants influence MPN risk, disease course, and leukemic transformation, highlighting their crucial role.

Area of Science:

  • Hematology
  • Genetics
  • Oncology

Background:

  • Myeloproliferative neoplasms (MPNs) are often linked to somatic mutations.
  • Hereditary thrombocytosis and erythrocytosis present clinically like MPNs but are not malignant.
  • Germline variants are increasingly recognized for their role in MPN development and progression.

Purpose of the Study:

  • To explore the role of hereditary factors in myeloproliferative neoplasms (MPNs) pathogenesis.
  • To investigate how germline variants influence MPN risk and clinical course.
  • To understand the interaction between germline factors and acquired mutations in MPNs.

Main Methods:

  • Review of existing literature on genetic factors in MPNs.
  • Analysis of studies identifying germline variants associated with hereditary thrombocytosis and erythrocytosis.
  • Examination of research on germline-somatic interactions in MPN pathogenesis.

Main Results:

  • Several mutations identified explain hereditary thrombocytosis and erythrocytosis.
  • Germline variants can modify the risk of leukemic transformation in MPNs.
  • Germline factors interact with acquired chromosomal aberrations, affecting disease course.

Conclusions:

  • Germline factors play a significant role in the pathogenesis of myeloproliferative neoplasms.
  • Understanding hereditary contributions is crucial for diagnosing and managing MPNs.
  • Germline variants are important determinants of MPN behavior and patient outcomes.

More Related Videos

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Mutations01:39

Mutations

Overview